Related Experiment Videos
Treatment of ocular inflammatory disorders with daclizumab
George N Papaliodis1, David Chu, C Stephen Foster
1Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA.
Purpose:
To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods).
Design:
Retrospective, nonrandomized case series.
Participants:
Fourteen patients.
Methods:
Fourteen patients were treated with daclizumab after previously failing standard treatment methods.
Main Outcome Measures:
Inflammation and visual acuity.
Results:
Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened.
Conclusions:
Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.
Insights
Daclizumab therapy showed potential for treating ocular inflammatory disorders in patients who failed other treatments. While some patients experienced improved visual acuity and reduced inflammation, others had continued vision loss.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Ocular inflammatory disorders often present challenges in treatment.
- Standard therapies may be insufficient for certain patients.
- Daclizumab offers a potential therapeutic option for refractory cases.
Purpose of the Study:
- To assess the safety and efficacy of daclizumab.
- To evaluate outcomes in patients with various ocular inflammatory conditions.
- To analyze results in patients with prior treatment failures.
Main Methods:
- Retrospective, nonrandomized case series.
- Fourteen patients with ocular inflammatory disorders were included.
- Treatment involved daclizumab after failure of standard methods.
Main Results:
- Visual acuity improved in 44% of eyes and 36% of patients.
- Inflammation improved in 59% of eyes.
- However, 22% of eyes and 27% of patients experienced continued visual loss.
Conclusions:
- Daclizumab appears to be a safe treatment option.
- It demonstrates potential efficacy for some patients with ocular inflammatory disorders.
- Further research may be warranted for specific indications.